Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
NCT02433236 · Rigel Pharmaceuticals · PHASE2 · withdrawn · last registry update 2015-10-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study withdrawn prior to enrollment of first subject” | – | Registry record, Rigel Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SYK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-10-10Results posted on the registry: Rigel Pharmaceuticals, R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% (NCT02040623)
- 2016-10-03Results posted on the registry: Rigel Pharmaceuticals, R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% (NCT01900249)
- 2016-09-29Results posted on the registry: Rigel Pharmaceuticals, Placebo + R940343 1mg (NCT01591044)
- 2016-07-15Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib disodium (R935788) + Placebo (NCT00665626)
- 2016-06-13Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib disodium (R935788) + Fostamatinib disodium (R935788) (NCT00665925)
- 2016-06-08Results posted on the registry: Rigel Pharmaceuticals, R932333 + Placebo (NCT01597050)
- 2014-12-18Results posted on the registry: Rigel Pharmaceuticals, fostamatinib (NCT00446095)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision